Novartis CEO Dials Up 5,000 Managers After Cohen Furor - Bloomberg
vasant narasimhan: Novartis CEO Jimenez to quit giving reins to Vasant Narasimhan - The Economic Times
Novartis 'focusing on high-end, innovative medicines,' CEO says
Six Questions For Novartis CEO Narasimhan :: Scrip
Novartis CEO Vas Narasimhan on M&A and Taking Earlier Risks on New Technology
Novartis CEO's $50 Billion of Deals Was Just the First Act - Bloomberg
The CEO of Novartis on Developing Drugs During a Pandemic | WIRED
Novartis' growth ills lay tricky treatment pathway | Reuters
Novartis's Vas Narasimhan on AI, Data Science for Company Operations
Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast | Fierce Biotech
Vas Narasimhan | LinkedIn
Amazon Web Services, Google, Microsoft cloud: How cloud services are boosting the pharma sector - BusinessToday - Issue Date: Apr 16, 2023
Novartis CEO Vasant Narasimhan on China's coronavirus outbreak
Can you hear me, pharma? Voice-enabled apps are on the rise—and please don't freak out about privacy | Fierce Pharma
Klaus Moosmayer, Ph.D. | Novartis
Novartis CEO Says FDA Process Could Have Been Handled Better - Bloomberg
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis to limit M&A spend to 5% of market value | Financial Times
Novartis Figuring Out How to Keep Brand Intact After Lobby Furor | IndustryWeek
Agenda Contributors | World Economic Forum
Watch CNBC's full interview with Novartis CEO Vas Narasimhan - YouTube
Top Novartis lawyer steps down over Michael Cohen payments | Novartis | The Guardian
Sunil Malewar | Paramount Rehabilitation Services
New generation pushes AI boundaries - Nikkei Asia
Novartis CEO Jimenez to step down early next year | The Seattle Times
